Drugs / EQ101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05589610 | Dec 2022 → Mar 2024 | alopecia areata, alopecia totalis, alopecia universalis | Equillium | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-06-04 | Equillium | Results Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata equilliumbio.com ↗
Results from the study demonstrated a favorable safety and tolerability profile with no serious adverse events (SAEs), and improvements in SALT scores above the published historically low placebo response rates. |
| 2022-11-03 | Equillium | Results Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit equilliumbio.com ↗
Preclinical and translational data supports EQ101 for the treatment of alopecia areata |
| 2022-10-26 | Equillium | Results Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference equilliumbio.com ↗
Treatment of PBMCs with EQ101 or EQ102 resulted in an approximate 50% decrease in proliferation of CD4 T cell subsets, and an approximate 40% decrease of CD8 subsets. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EQ101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05589610 ↗ |
| Route | Intravenous | “Study drug will be administered via intravenous (IV) push” NCT05589610 ↗ |